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A B S T R A C T
Hemophagocytic lymphohistiocytosis (HLH) is a rare inflammatory condition with tissue destruction due to
abnormal immune activation. We present a series of 2 cases of cytomegalovirus-induced HLH in children during
maintenance chemotherapy for acute lymphoblastic leukemia. These cases emphasize the importance of con-
sidering secondary HLH in this high-risk subset of pediatric patients.
Introduction
Hemophagocytic lymphohistiocytosis (HLH) is an inflammatory
condition with tissue inflammation and destruction due to abnormal
immune activation. It is characterized by fever, pancytopenia, spleno-
megaly, and hemophagocytosis in the bone marrow, liver, or lymph
nodes [1]. Infection, malignancy, and autoimmune conditions are
known triggers. There are a growing number of genetic mutations im-
plicated as predisposing factors. We present a series of 2 cases of HLH in
children with CMV infection undergoing treatment for acute lympho-
blastic leukemia (ALL). In our literature review, we can only find two
previous cases of CMV-induced HLH with patients undergoing treat-
ment for ALL. These cases emphasize the importance of considering
secondary HLH in this high-risk subset of patients.
Case 1
A seven-year-old male with high risk acute lymphoblastic leukemia
in remission on cycle 2 of maintenance therapy was admitted to an
outside hospital for persistent fever and pancytopenia: WBC 900/uL,
Hgb 9.8 g/dL, platelets 41 000/uL and absolute neutrophil count (ANC)
117/uL. His physical exam was unremarkable with the exception of
acute otitis media for which he was treated with intravenous cefepime.
Two peripheral blood cultures were negative. A respiratory PCR was
positive for rhinovirus. He was persistently febrile and he was then
transferred to our tertiary pediatric center. Pediatric infectious disease
was consulted. The patient underwent a CT scan of the sinuses, neck,
chest, and abdomen. It was remarkable for mild mucosal thickening
involving the maxillary sinuses bilaterally, nephromegaly, splenome-
galy, and gallbladder wall thickening. Antimicrobial coverage was
broadened to: vancomycin, piperacillin/tazobactam, and voriconazole.
Significant lab results included CMV quantitative DNA PCR 416,929
copies/mL, ferritin 25,246 ng/mL (reference range 7–140 ng/mL), LDH
1104 IU/L (reference range 104–333 IU/L), and triglycerides of
301 mg/dL (reference range Normal:< 150 mg/dL. Borderline high:
150–199 mg/dL. High: 200–499 mg/dL). A bone marrow aspirate and
biopsy yielded no evidence of hemophagocytosis or leukemia.
Fundoscopic examination revealed no signs of CMV retinitis.
Ganciclovir 400 mg twice daily was started to treat CMV viremia.
Within 48 h his fever resolved, a repeat CMV level at that time was
decreased to 6073 copies/mL. Genetic testing found no sentinel muta-
tions to suggest familial HLH.
He was continued on antiviral therapy at home for several weeks.
His regular maintenance chemotherapy was resumed and he had a full
recovery. He was re-hospitalized six months later for persistent re-
current cytomegalovirus infection and was treated with intravenous
foscarnet for two weeks and one month into outpatient oral therapy he
developed seizures so the foscarnet was discontinued at that time. At
his last follow up two years later he was clinically well and off any
therapy.
Case 2
A six and a half-year-old boy with high risk ALL in morphological
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and molecular remission had several episodes of myelosuppression
during maintenance chemotherapy. Attempts to mitigate this included
pentamidine instead of trimethoprim-sulfamethoxazole for pneumo-
cystis prophylaxis and maintenance chemotherapy doses of 6-MP and
methotrexate doses were reduced by 50%. During maintenance cycle
five he was admitted to the hospital with fever and pancytopenia. His
WBC was 0.7 × 103/μL, Hemoglobin 8.1 g/dL, Hct 23.2% and platelets
of 111 × 103/μL. Soon after admission, the patient developed hypox-
emia, and his chemotherapy was held. Chest radiography revealed bi-
lateral perihilar opacities and atelectasis. Cefepime and azithromycin
were started for pneumonia. On day 4 of admission, he developed he-
patosplenomegaly, mediastinal adenopathy, and nephromegaly.
Voriconazole was initiated for presumed invasive fungal disease.
Significant lab results include: include ferritin 40 000 ng/mL, CMV PCR
11 949 copies/mL, soluble IL-2r 11 000 U/mL (reference range
406–1100 U/mL) and a bone marrow biopsy revealed moderate he-
mophagocytosis (Fig. 1). He was started on 5 mg twice daily dex-
amethasone and intravenous ganciclovir twice daily, was failing to re-
spond and was switched to cidofovir and completed two weeks of
treatment. He also completed eight weeks of chemotherapy without
incident. Follow up labs including a CBC, soluble IL-2R receptor, fer-
ritin, fibrinogen and triglycerides were all within normal limits. At
discharge he had fully recovered and at his last follow up appointment
two years later he was alive and well.
Discussion
HLH is a clinical syndrome of immune dysregulation and hyper-
activation on the spectrum of sepsis and SIRS, derived from hypercy-
tokinemia with numerous possible etiologies, including genetic pre-
disposition, infection, autoimmunity, and immunodeficiency. Familial
HLH has multiple subtypes, and with advancement in genetic testing, it
is now understood that this can present at any age [1]. Im-
munodeficiency syndromes associated with HLH include: Chediak-Hi-
gashi syndrome, Griscelli syndrome, and X-linked lymphoproliferative
syndrome [1]. Autoimmune disease include systemic lupus er-
ythematosus, systemic sclerosis, dermatomyositis and Sjogren’s syn-
drome. Malignancies include acute lymphocytic leukemia, neuro-
blastoma, Hodgkin's disease and non-Hodgkin's lymphoma have also
been described [1]. Immunosuppressed patients undergoing che-
motherapy or post-transplant therapy are also at risk. In 2009 the
Histiocytic Society put forth the revised HLH-2004 criteria for diagnosis
as seen in Table 1.
The criteria are a collection of clinical, laboratory and histologic
features. Perhaps the most common signs are fever and splenomegaly.
Hepatomegaly, lymphadenopathy and a maculopapular rash have been
described as well [2]. Laboratory abnormalities are often most notable
for significant cytopenias. Elevated bilirubin, triglycerides, ferritin, and
lactate dehydrogenase are chemistry findings that suggest hemolysis.
Many patients with HLH present with shock or sepsis, and the clinical
presentation and laboratory values may initially suggest and infectious
process. NK cell activity as measured by flow cytometry and soluble
CD25 levels help differentiate these conditions [3]. In our two patients,
one had hemophagocytosis demonstrated on bone marrow biopsy, and
one did not. Both met criteria based on having fever, splenomegaly and
cytopenias and hyperferritinemia. This highlights the need for a diag-
nostic criteria based on multiple factors as bone marrow biopsy is not
sufficient in making this diagnosis.
The pathogenesis of HLH is not well understood. There is evidence
to suggest impairment in NK-cell activity leads to persistent activation
of macrophages and production of cytokines [4]. Infections, especially
viral, have been associated with reduced NK cell quantities, underlying
the basis for viral-associated HLH syndromes [5]. Previously reported
infectious organisms include parvovirus B19, herpes simplex virus
(HSV), varicella-zoster virus, Epstein-Barr virus, cytomegalovirus, in-
fluenza virus, coxsackie virus, fungi, parasites, rickettsiae, Myco-
bacterium tuberculosis and other bacteria, including Streptococcus pneu-
moniae. Most primary cases of HLH are secondary to infection [1].
Our two cases underscore the importance of recognizing secondary
infections in pediatric oncology patients as well as having a keen
awareness of the complications of secondary infections. The key to
treatment in most cases is to treat the underlying infection.
Pediatric oncology patients, in particular, remain at risk for these
infections as a result of immunosuppressive therapy. HLH often has a
poor prognosis, but fortunately if identified early, secondary types of
the hemophagocytic syndrome have a better prognosis than familial
types. Similar to patients in the present case series, Wakai et al. de-
scribed a pediatric patient who presented with persistent fever, leuko-
cytopenia and hepatosplenomegaly secondary to CMV-HLH with CMV
retinitis during maintenance therapy for T-ALL, with remission
achieved with dexamethasone and IVIG despite the persistence of CMV
retinitis [6]. Similarly, Kobayashi and colleagues describe a young pa-
tient with B-ALL presenting with persistent fever during maintenance
therapy. In this case, fever resolved with prednisolone with the devel-
opment of visual disturbance and discovery of CMV antigenemia sev-
eral days later [7]. In both cases as well as ours, ultimate eradication of
antigenemia required antiviral therapy.
In conclusion, secondary infections in pediatric oncology patients
should be very high on the differential of a patient with fevers. In the
presence of persistent fevers and lack of improvement despite appro-
priate therapy, further testing for HLH should be obtained. In both of
our cases, a markedly elevated ferritin level was an important
Fig. 1. Bone Marrow Aspiration: demonstrates adequate hypocellular bone marrow
(65%) showing trilineage hematopoiesis, marked histiocytosis, hemophagocytosis, ade-
quate iron stores and no malignancy.
Table 1
HLH-2004 revised diagnostic criteria. Of note, absence of hemophagocytosis in the bone
marrow does not exclude the diagnosis of HLH.
1. Molecular diagnosis consistent with HLH or genetic analysis consistent with
Familial Hemophagocytic Lymphohistiocytosis.
2. At least 3 of 4
Fever for ≥7 days
Splenomegaly
Cytopenia (≥2 lineages), anemia (Hb<9.0 g/dL)
Hepatitis
3. At least 1 of 4
Hemophagocytosis
Hyperferritinemia (≥500 μg/L)
Increased soluble CD25 > 2400 units/mL. (also known as sIL-2)
Low/absent natural killer cell activity
4. Findings supportive of HLH
Hypertriglyceridemia (≥265 mg/dL)
Hypofibrinogenemia (< 1.5 g/L)
Hyponatremia
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diagnostic indicator to pursue further diagnostic possibilities beyond
secondary infections. HLH, even viral induced, is a serious complication
of chemotherapy, but if identified and treated the overall prognosis is
excellent.
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